[go: up one dir, main page]

MX2022007179A - Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon. - Google Patents

Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon.

Info

Publication number
MX2022007179A
MX2022007179A MX2022007179A MX2022007179A MX2022007179A MX 2022007179 A MX2022007179 A MX 2022007179A MX 2022007179 A MX2022007179 A MX 2022007179A MX 2022007179 A MX2022007179 A MX 2022007179A MX 2022007179 A MX2022007179 A MX 2022007179A
Authority
MX
Mexico
Prior art keywords
sting
stimulator
modulators
heterocyclic compounds
interferon genes
Prior art date
Application number
MX2022007179A
Other languages
English (en)
Inventor
Luigi Piero Stasi
Marek Wronowski
Adam Radzimierski
Charles-Henry Fabritius
Magdalena Izabela Zawadzka
Maciej Krzysztof Rogacki
Grzegorz Wojciech Cwiertnia
Lukasz Piotr Dudek
Agnieszka Justyna Gibas
Anna Rajda
Tushar Ravindra Mahajan
Marcin Wojciech Les
Karol Zuchowicz
Synak David Jörg
Sundara Raghuram Tangirala
Original Assignee
Ryvu Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics S A filed Critical Ryvu Therapeutics S A
Publication of MX2022007179A publication Critical patent/MX2022007179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a constructos compuesto-ligante y conjugados de anticuerpo-fármaco de compuestos de la fórmula (I) que resultan útiles como moduladores de STING (estimulador de genes de interferón).
MX2022007179A 2019-12-11 2020-12-11 Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon. MX2022007179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19460066 2019-12-11
PCT/EP2020/085833 WO2021116446A1 (en) 2019-12-11 2020-12-11 Functionalized heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Publications (1)

Publication Number Publication Date
MX2022007179A true MX2022007179A (es) 2022-07-19

Family

ID=69137703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007179A MX2022007179A (es) 2019-12-11 2020-12-11 Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon.

Country Status (11)

Country Link
US (1) US20230055741A1 (es)
EP (1) EP4073062A1 (es)
JP (1) JP2023505877A (es)
KR (1) KR102886226B1 (es)
CN (1) CN114787148A (es)
AU (2) AU2020401358B2 (es)
BR (1) BR112022010839A2 (es)
CA (1) CA3159943A1 (es)
IL (1) IL293558B1 (es)
MX (1) MX2022007179A (es)
WO (1) WO2021116446A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238786A1 (en) 2018-06-12 2019-12-19 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
WO2020249773A1 (en) * 2019-06-12 2020-12-17 Ryvu Therapeutics S.A. Next-generation modulators of stimulator of interferon genes (sting)
CN113950473B (zh) * 2019-06-12 2025-07-22 雷沃医疗有限公司 干扰素基因刺激物(sting)的下一代调节剂
IL303332A (en) * 2020-12-04 2023-07-01 Dyne Therapeutics Inc Antibody-oligonucleotide complexes and their uses
CN113754574B (zh) * 2021-09-18 2024-03-19 苏州大学 一种绿色的可见光催化的乙酸酯化合物的制备方法
TW202342105A (zh) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 包含可用作sting激動劑的化合物的化合物-連接基構建體及其用途
CN115433124B (zh) * 2022-10-17 2024-08-06 常州佳德医药科技有限公司 一种4-氯-6-甲氧基-7-苄氧基喹啉的制备方法
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867224B1 (en) * 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
GB2563642A (en) * 2017-06-22 2018-12-26 Curadev Pharma Ltd Small molecule modulators of human STING
WO2019238786A1 (en) 2018-06-12 2019-12-19 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
AU2020276334B2 (en) 2019-05-10 2022-12-22 Henan Zhiwei Biomedicine Co., Ltd. Substituted 1-amino-1H-imidazole-5-carboxamide as Bruton's Tyrosine Kinase inhibitors
WO2020249773A1 (en) * 2019-06-12 2020-12-17 Ryvu Therapeutics S.A. Next-generation modulators of stimulator of interferon genes (sting)
JP7426486B2 (ja) * 2019-12-11 2024-02-01 ライブ・セラピューティクス・スプウカ・アクツィーナ インターフェロン遺伝子刺激因子（ｓｔｉｎｇ）のモジュレーターとしての複素環式化合物

Also Published As

Publication number Publication date
AU2024203206A1 (en) 2024-05-30
IL293558A (en) 2022-08-01
CA3159943A1 (en) 2021-06-17
EP4073062A1 (en) 2022-10-19
KR102886226B1 (ko) 2025-11-13
IL293558B1 (en) 2025-12-01
KR20220112824A (ko) 2022-08-11
AU2020401358A1 (en) 2022-05-26
US20230055741A1 (en) 2023-02-23
AU2020401358B2 (en) 2024-02-15
BR112022010839A2 (pt) 2022-09-13
WO2021116446A1 (en) 2021-06-17
JP2023505877A (ja) 2023-02-13
CN114787148A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2022007179A (es) Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon.
PH12019502870A1 (en) Small molecule modulators of human sting
NZ757357A (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2020009347A (es) Picolinamidas como fungicidas.
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2019011281A (es) Compuestos de dinucleotidos ciclicos modificados.
CR20220126A (es) Moduladores de sting (estimulador de genes de interferón)
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
PH12017501817B1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2021015761A (es) Polipeptidos.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MY182342A (en) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
EP3983078C0 (en) NEXT GENERATION INTERFERON GENE STIMULATOR (STING) MODULATORS
PH12019501362B1 (en) Polymorphs
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
EA202091428A1 (ru) Замещенные амиды ii пирролидина
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX2023002525A (es) Nuevos compuestos.
EA202091429A1 (ru) Замещенные амиды i пирролидина
CR20230509A (es) Compuestos heterocíclicos capaces de activar sting
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.